BTC Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is a selective EGFR tyrosine kinase inhibitor, which can block the signaling pathways activated by BTC-EGFR interaction, potentially leading to anti-proliferative effects and apoptosis in EGFR-dependent cells. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib inhibits the tyrosine kinase domains of both EGFR and HER2 receptors, disrupting the signaling pathways activated by BTC binding to EGFR. This can result in inhibited cell growth and induction of apoptosis. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Osimertinib targets EGFR tyrosine kinase and is selective for EGFR mutations. By inhibiting EGFR signaling, it potentially influences the effects of BTC binding to its receptor, leading to reduced cell proliferation and survival in EGFR-mutated cells. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets several tyrosine protein kinases, including EGFR. Its inhibition of EGFR could disrupt BTC-mediated signaling pathways, leading to anti-proliferative and pro-apoptotic effects. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase (RTK) inhibitor, which includes activity against EGFR. By inhibiting EGFR, Sunitinib can potentially disrupt BTCs signaling pathways, contributing to anti-tumor effects. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits the activity of several RTKs, including EGFR. Its blockade of EGFR signaling can indirectly influence the functional outcomes of BTC binding to its receptor, leading to reduced cell proliferation and increased apoptosis in certain cell types. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
BIBF1120 is a multi-targeted receptor tyrosine kinase inhibitor, affecting EGFR among others. By inhibiting EGFR, it could disrupt BTC-mediated signaling, potentially leading to anti-fibrotic and anti-tumor effects. | ||||||